FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis
There are approximately 160,000 patients in...

